aTyr Pharma Announces Third Quarter 2025 Results and Provides Corporate Update

Core Insights - The company reported results from the Phase 3 EFZO-FIT™ study of efzofitimod in pulmonary sarcoidosis, indicating that while the primary endpoint was not met, the therapy showed improvements in quality of life and reduced steroid use [3][4] - The company plans to meet with the FDA in the first quarter of 2026 to discuss the future development of efzofitimod based on the study results [3][4] - The company ended Q3 2025 with $92.9 million in cash and investments, reflecting a solid financial position [9][13] Clinical Development Updates - The Phase 3 EFZO-FIT™ study involved 268 patients and evaluated two dosages of efzofitimod, with clinical benefits observed in various efficacy parameters despite not meeting the primary endpoint [4][6] - The Phase 2 EFZO-CONNECT™ study is ongoing, targeting systemic sclerosis-related interstitial lung disease, with enrollment expected to complete in the first half of 2026 [4][6] Financial Performance - For Q3 2025, the company reported total revenues of $190,000, primarily from license and collaboration agreements, compared to $235,000 in the same period of 2024 [11] - Research and development expenses for Q3 2025 were $22.1 million, up from $14.8 million in Q3 2024, reflecting increased clinical trial costs [9][11] - The net loss for Q3 2025 was $25.7 million, compared to a net loss of $17.3 million in Q3 2024, indicating higher operational costs [11]